Patients receiving acid suppression therapy who are infected with Clostridium difficile have more severe disease and are more likely to die than patients who aren?t receiving the therapy, according to a study published in Clinical Infectious Diseases (2011;53[12]:1173-1178).
Patients, particularly older ones, receiving acid suppression therapy who are infected with Clostridium difficile have more severe disease and are more likely to die than patients who aren’t receiving the therapy, according to a study published in Clinical Infectious Diseases (2011;53[12]:1173-1178).
“Data published elsewhere have suggested that acid suppression therapy is a risk factor for CDI acquisition and relapse. These findings suggest an additional role in increased severity of disease, including mortality, and merit further study,” the authors conclude. Based on their results and previous research, they recommend that clinicians consider discontinuing acid suppression in patients with diagnosed or strongly suspected C difficile infection unless a contraindication, such as active peptic ulcer disease, exists.
The retrospective review of 485 cases of C difficile infection in patients between 1 and 99 years of age at the Naval Medical Center, San Diego, compared potential risk factors for complications (megacolon, surgery, intensive care unit stay, death) or death alone. Among the 47 patients who developed one or more complications and the 23 who died, the authors found independent associations between complications and acid suppression, hospitalization for C difficile infection, age 80 years or older, and corticosteroid use. Acid suppression and age 80 years or older were associated with higher odds of death.
Although more severe disease might be expected in patients with hospital-associated C difficile rather than infection diagnosed on admission, the authors found the opposite to be true. Patients admitted to the hospital with a primary diagnosis of C difficile infection had more than 4-fold higher odds of complications, though not a significantly greater risk of death.
Hormone therapy safety: Study finds potential benefits for senior women
April 24th 2024A recent large-scale study challenged age-related concerns, suggesting hormone therapy may offer safety and even benefits for menopausal women aged over 65 years, aligning with The Menopause Society's 2022 Position Statement.
Read More
Hyperoxygenation use not linked to neonatal outcomes
April 23rd 2024Recent research evaluated the impact of maternal hyperoxygenation on neonatal Apgar scores, revealing no significant enhancement in outcomes among women with pathologic fetal heart rate tracing and suggesting limited efficacy of hyperoxygenation therapy in this context.
Read More
Study finds antihypertensive treatment reduces uterine fibroids risk
April 23rd 2024A recent study revealed that patients with untreated or new-onset hypertension face elevated chances of uterine fibroid diagnosis, underscoring the potential of antihypertensive therapy in mitigating this risk among midlife individuals.
Read More